• Explore /
  • Poster
  • / First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.

First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.

Abstract Video & Slides Poster

Authors

null

Tibor Csoszi

County Oncology Centre, Hetényi Géza Hospital, Szolnok, Hungary

Tibor Csoszi , Thomas Powles , Ajjai Shivaram Alva , Daniel E. Castellano , Mustafa Ozguroglu , Peter H. O'Donnell , Yohann Loriot , Noah M. Hahn , Aude Flechon , Alejo Rodriguez-Vida , Ronald De Wit , Susanna Y. Cheng , Stephane Oudard , Christof Vulsteke , Evan Y. Yu , Jianxin Lin , Kentaro Imai , Blanca Homet Moreno , Arjun Vasant Balar , Petros Grivas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02335424 and NCT02853305

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 521)

DOI

10.1200/JCO.2022.40.6_suppl.521

Abstract #

521

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Peter H. O'Donnell

First Author: Thomas Powles

First Author: Yohann Loriot

First Author: Jacqueline Vuky